| Literature DB >> 28040700 |
Catherine S Diefenbach1, Joseph M Connors1, Jonathan W Friedberg1, John P Leonard1, Brad S Kahl1, Richard F Little1, Lawrence Baizer1, Andrew M Evens1, Richard T Hoppe1, Kara M Kelly1, Daniel O Persky1, Anas Younes1, Lale Kostakaglu1, Nancy L Bartlett1.
Abstract
The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN. Published by Oxford University Press 2016. This work is written by US Government employees and is in the public domain in the US.Entities:
Mesh：
Substances：
Year: 2016 PMID： 28040700 PMCID： PMC6059238 DOI： 10.1093/jnci/djw249
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506